Sodium iodide symporter (NIS)-mediated radionuclide ( 131I, 188Re) therapy of liver cancer after transcriptionally targeted intratumoral in vivo NIS gene delivery

Human Gene Therapy

Volumn 22, Issue 11, 2011, Pages 1403-1412

  Klutz, Kathrin ^a   Willhauck, Michael J ^a   Wunderlich, Nathalie ^a   Zach, Christian ^a   Anton, Martina ^b   Senekowitsch Schmidtke, Reingard ^b   Göke, Burkhard ^a   Spitzweg, Christine ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA FETOPROTEIN; IODINE 131; MESSENGER RNA; RADIOISOTOPE; RHENIUM 188; SODIUM IODIDE SYMPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLONOGENIC ASSAY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG HALF LIFE; FEMALE; GENE TARGETING; GENE TRANSFER; GENETIC LINKAGE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CANCER; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR GROWTH; TUMOR XENOGRAFT; VIRUS REPLICATION; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GENE THERAPY; HEP G2 CELLS; HUMANS; IODINE RADIOISOTOPES; LIVER NEOPLASMS; MICE; MICE, NUDE; PROMOTER REGIONS, GENETIC; RADIOISOTOPES; RHENIUM; RNA, MESSENGER; SYMPORTERS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

ADENOVIRIDAE;

EID: 81855166748     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2010.158     Document Type: Article

References (38)

1. Bates, D., and Maechler, M. (2010). lme4: Linear mixed-effects-models using S4 classes. R package version 0.999375-37. Available-at http://CRAN.R-project.org/package = lme4 (accessed-June 2011).
2. Castro, M.R., Bergert, E.R., Beito, T.G., et al. (1999). Monoclonal-antibodies against the human sodium iodide symporter: Utility-for immunocytochemistry of thyroid cancer. J. Endocrinol.-163, 495-504. (Pubitemid 30033745)
3. Cengic, N., Baker, C.H., Schutz, M., et al. (2005). A novel therapeutic-strategy for medullary thyroid cancer based on-radioiodine therapy following tissue-specific sodium iodide-symporter gene expression. J. Clin. Endocrinol. Metab. 90,-4457-4464. (Pubitemid 41159327)
4. Chen, L., Altmann, A., Mier, W., et al. (2006). Radioiodine therapy-of hepatoma using targeted transfer of the human-sodium/iodide symporter gene. J. Nucl. Med. 47, 854-862. (Pubitemid 46768449)
5. Dadachova, E., Nguyen, A., Lin, E.Y., et al. (2005). Treatment with-rhenium-188-perrhenate and iodine-131 of NIS-expressing-mammary cancer in a mouse model remarkably inhibited-tumor growth. Nucl. Med. Biol. 32, 695-700. (Pubitemid 41502974)
6. Dai, G., Levy, O., and Carrasco, N. (1996). Cloning and characterization-of the thyroid iodide transporter. Nature 379,-458-460. (Pubitemid 26039527)
7. Dingli, D., Diaz, R.M., Bergert, E.R., et al. (2003a). Genetically-targeted radiotherapy for multiple myeloma. Blood 102,-489-496.
8. Dingli, D., Russell, S.J., and Morris, J.C., III. (2003b). In vivo-imaging and tumor therapy with the sodium iodide symporter. J. Cell Biochem. 90, 1079-1086. (Pubitemid 37485046)
9. Dingli, D., Peng, K. W., Harvey, M.E., et al. (2004). Image-guided-radiovirotherapy for multiple myeloma using a recombinant-measles virus expressing the thyroidal sodium iodide symporter. Blood 103, 1641-1646. (Pubitemid 38268954)
10. Dwyer, R.M., Bergert, E.R., O'Connor, M.K., et al. (2005a). In vivo-radioiodide imaging and treatment of breast cancer xenografts-after MUC1-driven expression of the sodium iodide symporter. Clin. Cancer Res. 11, 1483-1489. (Pubitemid 40315230)
11. Dwyer, R.M., Bergert, E.R., O'Connor, M.K., et al. (2006a). Sodium iodide symporter-mediated radioiodide imaging and-therapy of ovarian tumor xenografts in mice. Gene Ther. 13,-60-66. (Pubitemid 41823852)
12. Dwyer, R.M., Bergert, E.R., O'Connor, M.K., et al. (2006b). Adenovirus-mediated and targeted expression of the sodiumiodide-symporter permits in vivo radioiodide imaging-and therapy of pancreatic tumors. Hum. Gene Ther. 17, 661-668. (Pubitemid 43967869)
13. Faivre, J., Clerc, J., Gerolami, R., et al. (2004). Long-term radioiodine-retention and regression of liver cancer after sodium-iodide symporter gene transfer in Wistar rats. Cancer Res. 64,-8045-8051. (Pubitemid 39446941)
14. Hart, I.R. (1996). Tissue specific promoters in targeting systemically-delivered gene therapy. Semin. Oncol. 23, 154-158. (Pubitemid 26087998)
15. Herve, J., Cunha, A.S., Liu, B., et al. (2008). Internal radiotherapy-of liver cancer with rat hepatocarcinoma-intestine-pancreas-gene as a liver tumor-specific promoter. Hum. Gene Ther. 19,-915-926.
16. Hingorani, M., Spitzweg, C., Vassaux, G., et al. (2010). The biology-of the sodium iodide symporter and its potential-for targeted gene delivery. Curr. Cancer Drug Targets 10,-242-267.
17. Kakinuma, H., Bergert, E.R., Spitzweg, C., et al. (2003). Probasin-promoter (ARR2PB)-driven, prostate-specific expression of the-human sodium iodide symporter (h-NIS) for targeted radioiodine-therapy of prostate cancer. Cancer Res. 63, 7840-7844. (Pubitemid 37466717)
18. Kang, J.H., Chung, J.K., Lee, Y.J., et al. (2004). Establishment of a-human hepatocellular carcinoma cell line highly expressing-sodium iodide symporter for radionuclide gene therapy. J. Nucl. Med. 45, 1571-1576.
19. Li, H., Peng, K.W., Dingli, D., et al. (2010). Oncolytic measles-viruses encoding interferon b and the thyroidal sodium iodide-symporter gene for mesothelioma virotherapy. Cancer Gene-Ther. 17, 550-558.
20. Mandell, R.B., Mandell, L.Z., and Link, C.J., Jr. (1999). Radioisotope-concentrator gene therapy using the sodium/iodide-symporter gene. Cancer Res. 59, 661-668. (Pubitemid 29076065)
21. Peerlinck, I., Merron, A., Baril, P., et al. (2009). Targeted radionuclide-therapy using a Wnt-targeted replicating adenovirus-encoding the Na/I symporter. Clin. Cancer Res. 15, 6595-6601.
22. Penheiter, A.R., Wegman, T.R., Classic, K.L., et al. (2010). Sodium iodide symporter (NIS)-mediated radiovirotherapy-for pancreatic cancer. AJR Am. J. Roentgenol. 195, 341-349.
23. Scholz, I.V., Cengic, N., Baker, C.H., et al. (2005). Radioiodine-therapy of colon cancer following tissue-specific sodium iodide-symporter gene transfer. Gene Ther. 12, 272-280. (Pubitemid 40220629)
24. Smanik, P.A., Liu, Q., Furminger, T.L., et al. (1996). Cloning of-the human sodium iodide symporter. Biochem. Biophys. Res. Commun. 226, 339-345. (Pubitemid 26331906)
25. Spitzweg, C., and Morris, J.C. (2002). The sodium iodide symporter:-Its pathophysiological and therapeutic implications. Clin. Endocrinol. 57, 559-574. (Pubitemid 35316971)
26. Spitzweg, C., Zhang, S., Bergert, E.R., et al. (1999). Prostatespecific-antigen (PSA) promoter-driven androgen-inducible-expression of sodium iodide symporter in prostate cancer cell-lines. Cancer Res. 59, 2136-2141. (Pubitemid 29217677)
27. Spitzweg, C., O'Connor, M.K., Bergert, E.R., et al. (2000). Treatment-of prostate cancer by radioiodine therapy after tissuespecific-expression of the sodium iodide symporter. Cancer-Res. 60, 6526-6530.
28. Spitzweg, C., Dietz, A.B., O'Connor, M.K., et al. (2001a). In vivo-sodium iodide symporter gene therapy of prostate cancer. Gene Ther. 8, 1524-1531. (Pubitemid 33061890)
29. Spitzweg, C., Harrington, K.J., Pinke, L.A., et al. (2001b). Clinical-review 132: The sodium iodide symporter and its potential-role in cancer therapy. J. Clin. Endocrinol. Metab. 86, 3327-3335. (Pubitemid 32673505)
30. Spitzweg, C., Baker, C.H., Bergert, E.R., et al. (2007). Imageguided-radioiodide therapy of medullary thyroid cancer after- carcinoembryonic antigen promoter-targeted sodium iodide-symporter gene expression. Hum. Gene Ther. 18, 916-924. (Pubitemid 47587318)
31. Therneau, T., and Lumley, T. (2009). survival: Survival analysis,-including penalised likelihood. R package version 2.35-4. Available-at http://CRAN.R-project.org/package = survival (accessed-June 2011).
32. Trujillo, M.A., O'Neal, M.J., McDonough, S., et al. (2010) A-probasin promoter, conditionally replicating adenovirus that-expresses the sodium iodide symporter (NIS) for radiovirotherapy-of prostate cancer. Gene Ther. 17, 1325-1332.
33. Unterholzner, S., Willhauck, M.J., Cengic, N., et al. (2006). Dexamethasone-stimulation of retinoic acid-induced sodium-iodide symporter expression and cytotoxicity of 131-I in breast-cancer cells. J. Clin. Endocrinol. Metab. 91, 69-78. (Pubitemid 43069120)
34. Wapnir, I.L, Goris M, Yudd A, et al. (2004). The Na2/I-symporter-mediates iodide uptake in breast cancer metastases and-can be selectively down-regulated in the thyroid. Clin. Cancer-Res 10, 4294-4302. (Pubitemid 38878866)
35. Weiss, S.J., Philp, N.J., and Grollmann E.F. (1984). Iodide-transport in a continuous line of cultured cells from rat thyroid. Endocrinology 114, 1090-1098. (Pubitemid 14134351)
36. Willhauck, M.J., Sharif Samani, B.R., Gildehaus, F.J., et al. (2007). Application of 188rhenium as an alternative radionuclide for-treatment of prostate cancer after tumor-specific sodium-iodide symporter gene expression. J. Clin. Endocrinol. Metab. 92, 4451-4458. (Pubitemid 350074769)
37. Willhauck, M.J., Samani, B.R., Wolf, I., et al. (2008a). The potential-of 211Astatine for NIS-mediated radionuclide therapy in-prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 35, 1272-1281.
38. Willhauck, M.J., Sharif Samani, B.R., Klutz, K., et al. (2008b). a-Fetoprotein promoter-targeted sodium iodide symporter-gene therapy of hepatocellular carcinoma. Gene Ther. 15,-214-223. (Pubitemid 351150044)